(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

• Diagnosed with one of the following advanced mastocytosis diagnoses by Eligibility Committee
  • Aggressive Systemic Mastocytosis (ASM)
  • Systemic Mastocytosis with an Associated Hematologic Neoplasm (SM-AHN)
  • Mast Cell Leukemia (MCL)
• Measurable disease according to modified IWG-MRT-ECNM criteria. (A subset of patients inevaluble per mIWG-MRT-ECNM will be included in the study).
• ECOG (0 to 3)
• Have clinically acceptable local laboratory screening results (clinical chemistry, hematology) within certain limits

• Persistent toxicity from previous therapy for AdvSM that has not resolved to ≤ Grade 1
• Associated hematologic neoplasm requiring immediate antineoplastic therapy
• Clinically significant cardiac disease
• Known positivity for the FIP1L1 PDGFRA fusion. Patients with eosinophilia without detectable KIT D816V mutation must demonstrate lack of PDGFRA fusion mutation prior to enrollment
• Seropositive for human immunodeficiency virus (HIV) 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody
• History of clinically significant bleeding event within 30 days before the first dose of study drug or need for therapeutic anticoagulation on study
• Diagnosed with or treated for malignancy other than the disease under study within the prior 3 years before enrollment
• Received any cytoreductive therapy or any investigational agent less than 14 days, and for cladribine, interferon alpha, pegylated interferon, and any antibody therapy less than 28 days, before screening bone marrow biopsy
• Received hematopoietic growth factor support within 14 days before the first dose of study drug
• Received strong CYP3A4 inhibitors or inducers within 14 days or 5 drug half-lives, whichever is longer, before the first dose of study drug
• Need for treatment with high dose steroids

Rollover Cohort

• Demonstrate AHN progression requiring immediate AHN-directed therapy while receiving bezuclastinib
• Demonstrated clinical benefit from bezuclastinib therapy
• Have clinically acceptable local laboratory screening results (clinical chemistry, hematology) within certain limits High-Risk Cohort
• Receiving or indicated for AHN-directed therapy.
• Diagnosed with one of the following pathologic diagnoses of SM-AHN:
  • Myelodysplastic syndrome (MDS) that is high- or very high-risk
  • Accelerated phase myeloproliferative neoplasm (MPN)
  • MDS with excessive blasts in bone marrow or peripheral blood
  • Chronic myelomonocytic leukemia-2 (CMML-2)
• Have clinically acceptable local laboratory screening results (clinical chemistry, hematology) within certain limits.

• Diagnosis of Philadelphia chromosome-positive malignancy
• Diagnosis of acute myeloid leukemia (AML)
• Appropriate for allogenic hematopoietic stem cell transplantation
• Any contraindication to selected concomitant therapy
• Rollover Cohort: Have not demonstrated acceptable tolerability of previous bezuclastinib therapy
• High-Risk Cohort: Previously treated with investigational therapy for AdvSM
• High-Risk Cohort: Previously treated with cytoreductive therapy and discontinued due to treatment-related toxicity
• High-Risk Cohort: Received any cytoreductive therapy or any investigational agent less than 14 days, and for cladribine, interferon alpha, pegylated interferon, and any antibody therapy less than 28 days, before screening or archival bone marrow biopsy